

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

**CLARIFICATION ANNOUNCEMENT TO
2026 INTERIM RESULTS ANNOUNCEMENT**

Reference is made to the interim results announcement of The United Laboratories International Holdings Limited for the six months ended 30 June 2026 dated 31 August 2026 (the “Results Announcement”).

Due to inadvertent clerical error, the capital commitments at 30 June 2026 as stated in Note 14 to Financial Statements should be corrected as below:

14. CAPITAL COMMITMENTS

As at 30 June 2026, the Group had commitments for capital expenditure of RMB1,044,131,000 (31 December 2025: RMB1,319,378,000) in respect of the acquisition of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements.

Save for above, the Board confirms that all other information contained in the Results Announcement remains unchanged.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 3 September 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.